Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis (ATMOS)

The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with…

Non-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $8,750

UCB Biopharma SRLNCT07720375

Phase 1

A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease

This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

Non-cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary Disease

Estimated

~$10 – $8,750

Genentech, Inc.NCT06603246

Phase 2

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) deli…

Non-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $8,750

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06559150

Phase 1

A Sequential, Phase 1a/1b, Double-blind, 2-part Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Rev-56 for Inhalation Compared With Placebo in Healthy Adult Participants and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic Pseudomonas Aeruginosa

This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult hea…

Healthy ParticipantsNon-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $8,750

Revagenix, Inc.NCT07709494

Phase 2

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)

This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with…

Non-cystic Fibrosis Bronchiectasis

Home-based, Digitally Delivered Breathing Training in People With Non-cystic Fibrosis Bronchiectasis: A Randomized Control Trial

The purpose of this research is to investigate whether a home-based and health coach supported specific breathing and respiratory muscle training program impro…

Non-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $6,250

Mayo ClinicNCT05860803

Phase 4

Effect of Hypertonic Saline on Mucociliary Clearance in Non-CF Bronchiectasis

The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lun…

BronchiectasisNon-cystic Fibrosis Bronchiectasis

Estimated

~$10 – $6,250

University of North Carolina, Chapel HillNCT06242795